ClinicalTrials.gg
CompletedNCT00048360Updated Feb 12, 2013

Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

A Phase 3 interventional study of Extended-release bupropion hydrochloride in Attention Deficit Disorder, sponsored by GlaxoSmithKline. Completed at 21 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-02-12.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Enrollment
192nd of 706
162 · median 70
Started
2002
with 6 others
Phase 3
121 of 807
4 open now
Registered
16th of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 192nd largest by enrollment of the 706 interventional ones that give a count, is one of 7 that started in 2002, is one of 121 in phase 3, and was the 16th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

This is a placebo controlled study evaluating the efficacy and safety of medication in adults with Attention-Deficit Hyperactivity Disorder (ADHD).

03

Conditions studied

  • Attention Deficit Disorder

Keywords

  • ADD
  • ADHD
  • attention deficit
  • hyperactivity
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be diagnosed with ADHD.

Exclusion criteria

Exclusion Criteria:

  • Patient has a current or past history of seizure disorder, brain injury, anorexia nervosa or bulimia.
  • Patient has a current diagnosis of Major Depressive Disorder (MDD).
  • Patient has a current primary diagnosis of, or received treatment for, Panic Disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD) or Acute Stress Disorder within the previous 12 months.
  • Patient has a lifetime diagnosis of bipolar disorder, schizophrenia or other psychotic disorders.
  • Patient has a positive urine test at screening for presence of illicit drugs or alcohol abuse during the past 12 months.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
162 participants
06

What researchers measure

Primary outcomes

  1. ADHD Rating Scale

Secondary outcomes

  1. Clinical Global Impressions -Severity and Improvement.

  2. Quality of Life Enjoyment and Satisfaction Questionnaire.

07

Study locations

21 sites
  • GSK Clinical Trials Call Center
    Phoenix, Arizona 85016, United States
  • GSK Clinical Trials Call Center
    Chula Vista, California 91910, United States
  • GSK Clinical Trials Call Center
    Lafayette, California 94549, United States
  • GSK Clinical Trials Call Center
    Northridge, California 91324, United States
  • GSK Clinical Trials Call Center
    Spring Valley, California 91978, United States
  • GSK Clinical Trials Call Center
    West Palm Beach, Florida 33407, United States
  • GSK Clinical Trials Call Center
    Paducah, Kentucky 42003, United States
  • GSK Clinical Trials Call Center
    Rockville, Maryland 20852, United States
  • GSK Clinical Trials Call Center
    Cambridge, Massachusetts 02138, United States
  • GSK Clinical Trials Call Center
    Worcester, Massachusetts 01655, United States
  • GSK Clinical Trials Call Center
    Omaha, Nebraska 68105, United States
  • GSK Clinical Trials Call Center
    Chapel Hill, North Carolina 27514, United States
  • GSK Clinical Trials Call Center
    Beachwood, Ohio 44122, United States
  • GSK Clinical Trials Call Center
    Cincinnati, Ohio 45267-0559, United States
  • GSK Clinical Trials Call Center
    Portland, Oregon 97209, United States
  • GSK Clinical Trials Call Center
    Bellaire, Texas 77401, United States
  • GSK Clinical Trials Call Center
    Houston, Texas 77007, United States
  • GSK Clinical Trials Call Center
    Salt Lake City, Utah 84132, United States
  • GSK Clinical Trials Call Center
    Burlington, Vermont 05405, United States
  • GSK Clinical Trials Call Center
    Woodstock, Vermont 05091, United States
  • GSK Clinical Trials Call Center
    Seattle, Washington 98104, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002, a primary completion of Jun 2003 and a completion of Jun 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2002
First posted
Oct 31, 2002
Start
Oct 2002
Primary completionActual
Jun 2003
CompletionActual
Jun 2003
Last update
Feb 12, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00048360
Lead sponsor
GlaxoSmithKline
First posted
Oct 31, 2002
Start date
Oct 2002
Primary completion
Jun 2003
Completion
Jun 2003
Last update
Feb 12, 2013

Study contacts

GSK Clinical Trial, MD
study chair · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupropion

Start the discussion